EP4277898A4 - Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders - Google Patents

Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders Download PDF

Info

Publication number
EP4277898A4
EP4277898A4 EP22740146.0A EP22740146A EP4277898A4 EP 4277898 A4 EP4277898 A4 EP 4277898A4 EP 22740146 A EP22740146 A EP 22740146A EP 4277898 A4 EP4277898 A4 EP 4277898A4
Authority
EP
European Patent Office
Prior art keywords
disorders
compositions
treating
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22740146.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4277898A1 (en
Inventor
Felix Jinhyun Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP4277898A1 publication Critical patent/EP4277898A1/en
Publication of EP4277898A4 publication Critical patent/EP4277898A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
EP22740146.0A 2021-01-15 2022-01-14 Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders Pending EP4277898A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163137915P 2021-01-15 2021-01-15
PCT/US2022/012516 WO2022155471A1 (en) 2021-01-15 2022-01-14 Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders

Publications (2)

Publication Number Publication Date
EP4277898A1 EP4277898A1 (en) 2023-11-22
EP4277898A4 true EP4277898A4 (en) 2024-12-11

Family

ID=82448695

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22740146.0A Pending EP4277898A4 (en) 2021-01-15 2022-01-14 Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders

Country Status (6)

Country Link
US (1) US20240307325A1 (https=)
EP (1) EP4277898A4 (https=)
JP (1) JP2024504632A (https=)
KR (1) KR20230148156A (https=)
CA (1) CA3204756A1 (https=)
WO (1) WO2022155471A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942821A (zh) * 2023-06-02 2023-10-27 深圳市第二人民医院(深圳市转化医学研究院) Sigmar1基因抑制剂在制备治疗或预防脂肪肝病的药物中的应用
WO2025194019A1 (en) * 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2026057679A1 (en) * 2024-09-11 2026-03-19 Institut National de la Santé et de la Recherche Médicale Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112122A1 (en) * 2016-12-16 2018-06-21 Drexel University Methods of identifying and treating tumors with sigma1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142861A1 (en) * 2011-12-05 2013-06-06 National Yang Ming University Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis
WO2014015157A2 (en) * 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP3745862B1 (en) * 2018-01-31 2024-06-26 Mayo Foundation for Medical Education and Research D1 dopamine receptor agonists for treating fibrotic pathologies
WO2020112846A1 (en) * 2018-11-27 2020-06-04 Northwestern University Small molecule modulators of sigma-1 and sigma-2 receptors and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112122A1 (en) * 2016-12-16 2018-06-21 Drexel University Methods of identifying and treating tumors with sigma1 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SALVINO JOSEPH M. ET AL: "Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 27, no. 10, 1 May 2017 (2017-05-01), Amsterdam NL, pages 2216 - 2220, XP055924389, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2017.03.030 *
See also references of WO2022155471A1 *
SELBY LUKE V. ET AL: "Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 29, no. 2, 27 January 2020 (2020-01-27), UK, pages 107 - 110, XP093219075, ISSN: 1354-3784, DOI: 10.1080/13543784.2020.1721457 *
VILLEMAIN LAURE ET AL: "Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ER[alpha] and HNF1[alpha]", CANCERS, vol. 12, no. 8, 7 August 2020 (2020-08-07), CH, pages 2213, XP093218582, ISSN: 2072-6694, DOI: 10.3390/cancers12082213 *

Also Published As

Publication number Publication date
CA3204756A1 (en) 2022-07-21
EP4277898A1 (en) 2023-11-22
WO2022155471A1 (en) 2022-07-21
JP2024504632A (ja) 2024-02-01
KR20230148156A (ko) 2023-10-24
US20240307325A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
EP4281464A4 (en) Compositions and methods for the treatment of metabolic and liver disorders
EP4373939A4 (en) Genome editing compositions and treatment methods for chronic granulomatous disease
EP4277898A4 (en) Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders
EP4250932A4 (en) BACTERIAL COMPOSITIONS DESIGNED TO TREAT GRAFT-VERSE-HOST DISEASE
EP4188368A4 (en) Compositions and methods for treating diseases and disorders
EP4401745A4 (en) METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS OR METABOLITES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP4165025A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
EP3836965A4 (en) Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
EP3986439A4 (en) COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF BRAIN DISEASES
EP3866852A4 (en) COMPOSITIONS AND METHODS OF TREATING HEPATIC DISEASES
EP3740592A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE
EP4045094A4 (en) COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASE
EP4429763A4 (en) COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS
EP4097236A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES
EP4437108A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
EP3917923A4 (en) Compounds, compositions and methods for treatment of myopia
EP4188346A4 (en) NOBILETINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF COVID-19 AND RELATED PATHOLOGIES
EP4210755A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS
EP3568138A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ILLNESSES OR DISORDERS ASSOCIATED WITH MYELIN AND INFLAMMATION
EP4465997A4 (en) Bacterial compositions and methods of treating cancer and immune diseases
EP4340835A4 (en) Methods and compositions for treating cardiovascular disease
EP4340897A4 (en) Methods and compositions for treating pancreatic and hepatic disease
EP4228696A4 (en) COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS
EP4000629C0 (en) COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE (NAFLD)
EP4561557A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103426

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0231560000

Ipc: A61K0031155000

A4 Supplementary search report drawn up and despatched

Effective date: 20241113

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/92 20060101ALI20241107BHEP

Ipc: C07D 401/14 20060101ALI20241107BHEP

Ipc: C07D 231/56 20060101ALI20241107BHEP

Ipc: A61K 31/713 20060101ALI20241107BHEP

Ipc: A61K 31/7105 20060101ALI20241107BHEP

Ipc: A61K 31/352 20060101ALI20241107BHEP

Ipc: A61K 31/155 20060101AFI20241107BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260129